Patent · US Active

Apelin polypeptides

US11807693B2 · kind B2 · utility

0Cited by

43References

6Claims

0Family size

Assignee

AMGEN INC. · US

Inventors

Jerry Ryan HOLDER · Simi Valley, US
Gayathri Swaminath · Brisbane, US
Michael J. Frohn · Thousand Oaks, US
Brian Alan LANMAN · Calabasas, US
Anthony B. Reed · Newbury Park, US
Leslie P. Miranda · Thousand Oaks, US
John Gordon Allen · Newbury Park, US
Alexander J. Pickrell · Westlake Village, US
Aaron C. Siegmund · Ventura, US
Lewis D. Pennington · Ventura, US
Bryant Yang · Simi Valley, US

Key dates

Filing date	Jan 28, 2021
Grant date	Nov 7, 2023
Priority date	—
Expiry date	Mar 20, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.